A few things struck us while gathering this year's class of the Fierce 15, our 12th annual take on some of the most noteworthy private biotech upstarts making headway these days. First, you'll find a higher than usual accumulation of early-stage companies in the group. And it's not hard to see why. Once the IPO window opened in early 2013, we saw a whole slew of earlier winners jump through--many like bluebird and Agios winning some extraordinary returns for investors. By the end of last year we were beginning to see plenty of other newcomers make the move as well, definitely winnowing out the number of more advanced companies to select from.
Welcome to the latest edition of our weekly EuroBiotech Report. Cash-starved European cancer startups had reason to cheer this week when Aglaia Biomedical Ventures revealed a new, €65 million ($84 million) oncology fund. The Dutch VC shop plans to invest the cash pool--which could rise to €100 million--in up to 15 early-stage biotechs. Affimed Therapeutics had less success raising money. The German immuno-oncology biotech raised $56 million (€43 million) in its Nasdaq IPO, well short of the $75 million it hoped to pocket. Evotec wants money too and is willing to take legal action to get what it thinks it is due. The German company committed to taking legal steps against Israel's Andromeda Biotech in relation to allegations of misconduct made by Hyperion Therapeutics. Our final two stories cover the pros and cons of cross-border collaboration. Ernst & Young called for Nordic life science clusters to collaborate more closely, while in the United Kingdom the industry fretted about the prospect of Scottish independence. And more. Read the full EuroBiotech Report >>
The big question right now in biopharma is where real innovation is coming from, and nothing says innovation quite like a blockbuster sales estimate on a high-profile, late-stage program with some near-term potential for approval.
In recent years it's been the big biotechs in the U.S. which have registered approvals for the drugs most likely to succeed on the market. But in reviewing EvaluatePharma's recent picks for top Phase III drugs, it's interesting to see some prominent positions among the Big Pharma crowd.
POPULAR COMMENT THREADS
An embattled Eli Lilly won a major battle today, gaining the FDA's approval to market dulaglutide for Type 2 diabetes. It will be sold as Trulicity. Read more >>
Tekmira, developer of an RNAi treatment for Ebola, has come to terms with regulators on an access program for its in-development drug, allowing the company to provide doses to patients who have contracted the deadly virus.
Bolstered by a breakthrough drug designation at the FDA, Amgen is following through with a new drug application for its leukemia drug blinatumomab, hoping that promising Phase II data will be enough to push this program past the goal line on a greatly accelerated development schedule.
While Eylea brings in the money and the cardio contender alirocumab grabs the headlines, Regeneron believes one of its less heralded pipeline treatments could eventually outgrow both, treating the underlying cause behind a handful of chronic diseases.
Auxilium Pharmaceuticals has no intention of accepting a multibillion-dollar bid from Endo, the company said, preferring to stay the course and pull off an en-vogue tax inversion as it looks to cut costs.
Merck KGaA has come up with its long-awaited buyout deal, acquiring the life sciences services outfit Sigma-Aldrich for $17 billion.
From Our Sister Sites
Amgen is hoping to redeem its drug development rep by going to the FDA with an application for its new leukemia drug blinatumomab based on promising Phase II data, FierceBiotech reports.
Generic drugmaker Par Pharmaceutical is throwing in the towel in its long-running fight with Santarus ($SNTS) over its heartburn med Zegerid, and $100 million along with it. It reported today that the payment will settle their back-and-forth patent suit.